In Brief: Cordis
This article was originally published in The Gray Sheet
Executive Summary
Cordis: Firm's three-dimensional electrophysiology mapping technology, acquired through an August licensing agreement with Biosense ("The Gray Sheet" Aug. 7, In Brief), "has been successfully tested in initial human clinical cases" in Israel, Cordis says. "A three-dimensional reconstruction" of the right atrium's electrical activity with 35 data points were successfully produced in two patients, the firm says. The maps were produced within five minutes, the company states, noting that "with conventional electrophysiology, such a mapping procedure could take as much as two hours to perform." Additional trials slated for the next several weeks will "involve mapping of atrial fibrillation and ventricular tachycardias," Cordis says...